ENSC - Ensysce Biosciences, Inc. Stock Price, Fair Value and News

$1.570.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ENSC Price Action

Last 7 days

-11.3%

Last 30 days

-27.0%

Last 90 days

-27.0%

Trailing 12 Months

-81.0%

ENSC RSI Chart

ENSC Valuation

Market Cap

5.6M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

1.24

EV/EBITDA

2.93

Price/Free Cashflow

-0.97

ENSC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ENSC Fundamentals

ENSC Revenue

Revenue (TTM)

4.5M

Rev. Growth (Yr)

-85.58%

Rev. Growth (Qtr)

-64.04%

ENSC Earnings

Earnings (TTM)

-11.0M

Earnings Growth (Yr)

-663.51%

Earnings Growth (Qtr)

-115.12%

ENSC Profitability

EBT Margin

44.26%

Return on Equity

-1.3K%

Return on Assets

-345.11%

Free Cashflow Yield

-102.87%

ENSC Investor Care

Shares Dilution (1Y)

171.37%

Diluted EPS (TTM)

-5.39

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	6.2M	7.4M	4.5M	0
2024	1.7M	1.4M	4.4M	5.2M
2023	2.7M	3.0M	3.1M	2.2M
2022	3.9M	3.6M	2.7M	2.5M
2021	3.8M	3.7M	3.6M	3.5M
2020	0	0	0	3.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.

CEO	Dr. D. Lynn Kirkpatrick Ph.D.
WEBSITE	ensysce.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	7

Ensysce Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Ensysce Biosciences, Inc.? What does ENSC stand for in stocks?

ENSC is the stock ticker symbol of Ensysce Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ensysce Biosciences, Inc. (ENSC)?

As of Wed Dec 03 2025, market cap of Ensysce Biosciences, Inc. is 5.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENSC stock?

You can check ENSC's fair value in chart for subscribers.

Is Ensysce Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENSC is over valued or under valued. Whether Ensysce Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ensysce Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENSC.

What is Ensysce Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ENSC's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 1.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENSC PE ratio will change depending on the future growth rate expectations of investors.